enfortumab,cisplatin,pembrolizumab,carboplatin,gemcitabine
seagen,astellas,merck
['muc ,(-much)', 'pembro', 'ev-103']
ev-103 cohort k: 1l ev+/-pembro for la/muc extended f/u (n=149) orr: 65% vs 45% 12mo pfs: 55% vs 40% 12mo os: 82% vs 70% gr 3teaes: 65% vs 47% gr 3: skin reaction (21% vs 7%), hyperglycemia (6.6 vs 9.6%), peripheral neuro (2.6 vs 2.7%) #asco23 
MD, MSc | @UofTUrology @SUO_YUO Fellow & @IHPMEUofT CEHCR PhD| Previously: @MCG_Urology and @AUB_Lebanon 🇱🇧